nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

17.08.2023 | short review

ASCO 2023: new treatment options in CNS tumors

Invited short review

verfasst von: Dr. Josef Pichler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

Practice-changing therapy for IDH1/2–mutant diffuse glioma was presented at the meeting. Vorasidenib as an oral, brain penetrant, dual inhibitor of mutant IDH1/2 showed very promising results in the phase 3 INDIGO study. Other new treatment approaches including vaccines, immunotherapy and targeted therapy in rare von Hippel–Lindau-associated cerebral hemangioblastomas have shown progress in neuro-oncology.

Vorheriger Artikel Supportive management

Nächster Artikel Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

Yan H, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009;360:765–73.CrossRefPubMedPubMedCentral

Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.CrossRefPubMed

Buckner JC, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344–55.CrossRefPubMedPubMedCentral

Mellinghoff IK, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023; https://doi.org/10.1056/NEJMoa2304194.CrossRefPubMed

Wakimoto H, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898–909.CrossRefPubMedPubMedCentral

Alden RS. Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. Front Oncol. 2022;12:1070514.CrossRefPubMedPubMedCentral

ClinicalTrials.gov Identifier: NCT03922555; ASTX727 in Recurrent/Progressive Non enhancing IDH Mutant Gliomas

ClinicalTrials.gov Identifier: NCT05406700 Niraparib In Recurrent IDH 1/2 Gliomas

Titel: ASCO 2023: new treatment options in CNS tumors
Invited short review
verfasst von: Dr. Josef Pichler
Publikationsdatum: 17.08.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00915-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

HER2 in focus—gastric cancer

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

Management of malignant hypercalcemia in cancer patients—a short review

Prostate cancer special—part 1

Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors